Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease.

Next Previous
Search
Trial Profile

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topiramate (Primary) ; Amantadine
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Oct 2009 Actual initiation date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Planned initiation date changed from 1 Dec 2008 to 1 Jul 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top